Sanuj Ravindran

Chief Executive Officer-in-Residence at Bridgebio Pharma LLC

Sanuj Ravindran

Sanuj Ravindran

Chief Executive Officer-in-Residence at Bridgebio Pharma LLC

Overview
Career Highlights

PellePharm, Inc.

RelSci Relationships

1586

Number of Boards

8

Birthday

1972

Age

46

Number of Awards

1

Relationships
RelSci Relationships are individuals Sanuj Ravindran likely has professional access to. A relationship does not necessarily indicate a personal connection.

Venture Partner at Radius Ventures LLC

Relationship likelihood: Strong

Co-Founder at PellePharm, Inc.

Relationship likelihood: Strong

Co-Founder & Director at PellePharm, Inc.

Relationship likelihood: Strong

Co-Founder at Bridgebio Pharma LLC

Relationship likelihood: Strong

Treasurer at MyoTherix, Inc.

Relationship likelihood: Strong

Senior Analyst at Mehta Partners LLC

Relationship likelihood: Strong

Co-Founder at Radius Ventures LLC

Relationship likelihood: Strong

Professional at LR Management Company LLC

Relationship likelihood: Average

Director at Burrill & Co. LLC

Relationship likelihood: Average

Professor, Law School at Pace University - New York

Relationship likelihood: Average

Paths to Sanuj Ravindran
Potential Connections via
Relationship Science
You
Sanuj Ravindran
Chief Executive Officer-in-Residence at Bridgebio Pharma LLC
Education
MBA

The Kellogg School of Management (The Kellogg School or Kellogg) is the business school of Northwestern University in Evanston, Illinois, with additional campuses in downtown Chicago, Illinois and Miami, Florida. Kellogg offers full-time, part-time, and executive programs, and partners with schools in China, France/Singapore, India, Hong Kong, Israel, Germany, Canada, and Thailand.Founded in 1908 in downtown Chicago as a part-time evening program, the school was chartered to educate business leaders with "good moral character.

BA with Honors

Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. In 1853 the founders purchased a 379-acre tract of land on the shore of Lake Michigan 12 miles north of Chicago. They established a campus and developed the land near it, naming the surrounding town Evanston in honor of one of the University's founders, John Evans. After completing its first building, its first building in 1855, Northwestern began classes that fall with two faculty members and 10 students. Northwestern has three campuses and a total of 12 Schools and Colleges (one of which is located in South Florida. Two campuses are located on Lake Michigan, a 240-acre campus in Evanston, the first suburb north of Chicago, and a 25-acre campus in Chicago. One campus is located in Doha, Qatar. Northwestern University combines innovative teaching and pioneering research in a highly collaborative environment that transcends traditional academic boundaries. It provides students and faculty exceptional opportunities for intellectual, personal and professional growth in a setting enhanced by the richness of Chicago.

Memberships
Fellow
Current

The Society of Kauffman Fellows is a network of venture capitalists operating at 160 venture firms and corporate venture groups in 26 countries on 6 continents, collectively deploying $50B in venture capital.

Career History
Chief Executive Officer
2018 - Current

PellePharm is developing patidegib, a novel hedgehog pathway inhibitor, to mitigate the tumor burden in patients with basal cell carcinomas (BCCs), including those in Gorlin Syndrome, a devastating rare genetic skin disease. The company is focused on developing and commercializing this treatment to reduce the burden of disease and improve quality of life by potentially reducing invasive and painful surgeries and the scarring that often accompanies them. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from Infinity Pharmaceuticals. Patidegib is currently being studied in a phase 2 clinical trial for the treatment of sporadic BCCs.

Chief Executive Officer-in-Residence
2018 - Current

BridgeBio Pharma LLC discovers and develops pharmaceutical drugs for patients with genetic diseases. The firm offers transthyretin stabilizer, SHP2 inhibitor, KRAS inhibitor, Collagen 7 replacement, and S1P-lyase inhibitor. The company was founded by Neil Kumar and is headquartered in Palo Alto, CA.

Chief Business Officer
2016 - 2017

aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of innovative therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler in 2005 and is headquartered in San Diego, CA.

Boards & Committees
Member, Advisory Board
Current
Member, Board of Directors
Prior

Burrill & Co.'s venture capital activities focus exclusively on life science companies whose technologies and products are applicable across range of life science sub-sectors including: (1) human healthcare therapeutics and diagnostics/devices (2) health/wellness (3) agricultural biotechnology (4) biofuels and (5) industrial biotechnology, biomaterials and bioprocesses. In addition, to sector diversification, the firm also diversifies across investment stage. In general, most of their investments are in the start-up through mezzanine stage. Most of the firm's investments are made in series A and B rounds. They do invest in public entities. Burrill & Co. principally invests in the US and Europe. The firm's professionals usually serve on the board of directors of each portfolio company and, when necessary, assist with operational activities. Investments tend to average from $5 million to $15 million over the life of a company.Burrill & Co.'s private equity investments focus on investments in undervalued small-cap and mid-cap public companies and selected buy-outs and spin-outs from pharmaceutical, biotechnology and other life sciences entities. The firm seeks to acquire significant equity positions often through PIPEs and to optimize opportunities for future equity financing, acquisitions and divestitures.

Board Member
Prior

Resolvyx Pharmaceuticals, Inc. discovers and develops therapeutics for inflammatory diseases. Its products include RX-10001, RX-10045 and RX-20001. The firm's focus is to develop a new class of medicines called Resolvins for the treatment of a range of ophthalmic diseases. The company was founded by Daniel Goodman, Charles N. Serhan, Per Gjorstrup and Thomas E. Van Dyke in 2005 and is headquartered in Cambridge, MA.

Transactions
Details Hidden

aTyr Pharma, Inc. raised money in a private placement transaction

Awards & Honors
Board Certification - American Board of Internal Medicine